Visit 1 - Screening During the screening visit, the principal investigator and/or delegated staff must provide a copy of the IRB-approved informed consent form * to the subject before performing any study procedure.~* IRB must provide a certificate action as proof of approval of the informed consent form.~The study subject should take enough time to read this essential document. If the study subject agrees to participate in the clinical trial, after reading the document, he/she must sign it. By giving his/her signature, study subject allows the principal investigator and/or designated staff to perform the following study procedures:~Collection of medical history and demographic information.~Collection of prior (up to a week before screening) and current medications.~Evaluation of Inclusion and Exclusion Criteria.~Measurement of Weight in lb. and Height in inches.~Collection of vital signs, including respiratory rate, pulse rate, SPO2, blood pressure and body temperature.~Collection of laboratory samples, including Comprehensive Metabolic Panel, Complete Blood Count and Coagulation Panel, C - reactive protein and Erythrocyte sedimentation rate, and urine pregnancy test if female of childbearing potential.~Completion of Patient Questionnaires, VAS of Symptom's and Fatigue Scale.~Physical Examination by the principal investigator.~Adverse Events Monitoring. Within a 28-day period, all screening data should be collected and analyzed, and the principal investigator must decide whether the screened subject is eligible to participate in this Intermediate- Size Patient Population Expanded Access Protocol.~Visit 2, 3, 4*, 5 and 6. (Infusions 1, 2, 3*, 4 and 5) Throughout these visits, the principal investigator and/or delegated staff will perform the following assessments:~Pre-Infusion Check List~Update Medical History Form if necessary.~Update Concomitant medications list if applicable. (no premedication necessary for the infusions)~Measurement of Weight in lb.~Collection of vital signs, including respiratory rate, pulse rate SPO2, blood pressure and body temperature.~Completion VAS of Symptom's and Fatigue Scale.~Physical Examination by the principal investigator.~Investigational Product Administration:~Drug Name: HB-adMSCs~Route: Intravenous~Dose: 200 million.~24 hours telephone encounter after Investigational Product Administration to assess incidence of adverse events or serious adverse events.~Adverse Events monitoring.~At Visit 4/Infusion 3: Collection of laboratory samples, including Comprehensive Metabolic Panel, Complete Blood Count and Coagulation Panel, C - reactive protein, Erythrocyte sedimentation rate, urine pregnancy test female of childbearing potential and Patient Questionnaire.~Visit 7 (Follow up 1/Phone call)~Update Medical History Form if necessary.~Update Concomitant medications list if applicable.~Adverse Events monitoring.~Visit 8. (End of Study)~Update Medical History Form if necessary.~Update Concomitant medications list if applicable.~Measurement of Weight in lb.~Collection of vital signs, including respiratory rate, pulse rate, SPO2, blood pressure and body temperature.~Collection of laboratory samples, including Comprehensive Metabolic Panel, Complete Blood Count and Coagulation Panel, C - reactive protein, Erythrocyte sedimentation rate and urine pregnancy test if female of childbearing potential.~Completion of Patient Questionnaires, VAS of Symptom's and Fatigue Scale.~Physical Examination by the principal investigator.~Adverse Events monitoring.
This is an Intermediate- Size Patient Population Expanded Access Protocol to evaluate the safety and efficacy of HB-adMSCs for the treatment of patients with Post-COVID-19 Syndrome. The investigational product will be an add-on treatment to the standard of care.